CHILDREN'S ZYRTEC ALLERGY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHILDREN'S ZYRTEC ALLERGY (CHILDREN'S ZYRTEC ALLERGY).
Cetirizine is a selective antagonist of peripheral H1 histamine receptors, inhibiting histamine-mediated allergic and inflammatory responses.
| Metabolism | Cetirizine undergoes minimal hepatic metabolism; approximately 60% is excreted unchanged in urine, with minor metabolism via oxidative O-dealkylation. |
| Excretion | Primarily renal (60% unchanged) via tubular secretion; 40% metabolized in liver to inactive metabolites excreted in urine; <1% fecal. |
| Half-life | Terminal half-life 8.5–10.5 hours in children 2–5 years; 9–11 hours in children 6–12 years; 8–9 hours in adults. Clinically, supports once-daily dosing. |
| Protein binding | 88–96% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.3–0.6 L/kg (children); 0.4–0.8 L/kg (adults). Indicates extensive distribution into tissues, not limited to plasma. |
| Bioavailability | Oral bioavailability approximately 70% (range 60–80%) due to first-pass metabolism. |
| Onset of Action | Oral: 1 hour for antihistaminic effect; peak suppression of histamine-induced wheal at 2–4 hours. |
| Duration of Action | 24 hours for symptom relief; some effect persists up to 48 hours for wheal suppression. |
| Molecular Weight | 388.89 |
5 mg (1 tablet or 5 mL oral solution) once daily; dosing frequency may be increased to 10 mg once daily (2 tablets or 10 mL) for more severe symptoms.
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | For GFR 30–49 mL/min: 5 mg once daily. For GFR <30 mL/min or end-stage renal disease: 5 mg every other day. Not recommended for patients on dialysis. |
| Liver impairment | No adjustment required for mild hepatic impairment. For moderate to severe impairment (Child-Pugh B or C): 5 mg once daily. |
| Pediatric use | 6 months to <2 years: 2.5 mg (1/2 tablet or 2.5 mL) once daily; 2 to <6 years: 2.5 mg twice daily or 5 mg once daily; 6 years and older: 5–10 mg once daily based on symptom severity. |
| Geriatric use | In geriatric patients with normal renal function: no dose adjustment needed. For patients ≥65 years with renal impairment, follow renal adjustment guidelines. Due to potential anticholinergic effects, use with caution and consider lower starting dose (5 mg once daily) if sensitive. |
| 1st trimester | Cetirizine is generally considered safe; no increased risk of major malformations observed. |
| 2nd trimester | No known risk during second trimester; preferred antihistamine when needed. |
| 3rd trimester | Avoid near term due to potential for sedation or withdrawal symptoms in neonate. |
Clinical note
Comprehensive clinical and safety monograph for CHILDREN'S ZYRTEC ALLERGY (CHILDREN'S ZYRTEC ALLERGY).
| Placental transfer | Cetirizine crosses the placenta, but limited data suggest low transfer. |
| Breastfeeding | Cetirizine is excreted into breast milk in low amounts (less than 10% of maternal weight-adjusted dose). No adverse effects reported in infants; however, monitor for drowsiness. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to cetirizine or any componentSevere renal impairment (CrCl <10 mL/min)
| Precautions | Use caution in patients with renal impairment (CrCl < 11 mL/min) or hepatic impairment; dose adjustment recommended., Avoid use with alcohol or CNS depressants due to potential additive sedation., May cause drowsiness; patients should avoid driving or operating machinery until tolerance is established. |
| Food/Dietary | No significant food interactions. Take with or without food. Grapefruit juice does not affect cetirizine levels. |
| Clinical Pearls |
Loading safety data…
| L2 (Safer) |
| Teratogenic Risk | Animal studies have not demonstrated teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Cetirizine crosses the placenta. First trimester: no increased risk of major malformations reported in human data. Second and third trimesters: no specific fetal risks documented; however, use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. Monitor for maternal sedation or anticholinergic effects. |
| Fertility Effects | No significant impact on fertility reported in animal studies; human data lacking. |
| Cetirizine is a second-generation antihistamine with minimal anticholinergic effects. Onset of action within 1 hour; duration ~24 hours. Dose adjustment required for renal impairment (CrCl <30 mL/min: 5 mg once daily). Not significantly metabolized by CYP450; low drug interaction potential. |
| Patient Advice | Take once daily at the same time; may cause drowsiness in some children, so observe initial response before driving or operating machinery. · Do not exceed recommended dose; overdose may cause severe drowsiness, agitation, or seizures. · Store at room temperature, away from moisture and heat; keep out of reach of children. · If symptoms persist >7 days or worsen, consult a healthcare provider. · Avoid concurrent use with alcohol or other CNS depressants. |